Table 1.
Patient Demographics, Baseline Characteristics, and Disposition
| Characteristic | No. | % |
|---|---|---|
| Patients | 28 | |
| Age, years | ||
| Median | 63 | |
| Range | 41-77 | |
| Male | 18 | 64 |
| Years since first MM diagnosis | ||
| Median | 3.5 | |
| Range | 1.1-11.4 | |
| No. of prior MM therapies | ||
| Median | 2 | |
| Range | 1-3 | |
| ≥ 2 | 18 | 64 |
| Prior bortezomib | 11 | 39 |
| Prior lenalidomide | 13 | 46 |
| Prior autologous stem-cell transplantation | 19 | 68 |
| Refractory to last therapy | 12 | 43 |
| ECOG PS | ||
| Median | 1 | |
| Range | 0-2 | |
| High-risk cytogenetics* | 10 | 36 |
| Patient disposition | ||
| Cycles of therapy | ||
| Median | 6 | |
| Range | 1-32 | |
| Remaining on therapy | 2 | |
| Completed/discontinued therapy | 26 | |
| Disease progression | 9 | |
| Adverse event | 7† | |
| Investigator decision | 3‡ | |
| Patient decision | 7§ | |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; MM, multiple myeloma; PS, performance status.
*
Defined as del13 by metaphase or t(4;14), t(14;16), or del17p by fluorescent in situ hybridization.
†
Adverse events: one each of peripheral neuropathy, sepsis, acute myocardial infarction, hypercalcemia, gastroenteritis, pain in extremity, peripheral sensory neuropathy.
‡
Investigator decision: two with weight loss, one with painful neuropathy.
§
Patient decision: two moved, one desired natural remedy, four withdrew consent.